Ochratoxin A is a thermoresistant mycotoxin produced by ubiquitous molds of Aspergillus and Penicillium genera. It contaminates foodstuffs and feedstuffs worldwide and therefore is of human and animal concern.
Ochratoxin A induces oxidative stress, inflammation, and fibrosis, and is nephrotoxic, hepatotoxic, and neurotoxicin particularly in male subjects. Toxicity is mainly exerted through epigenetic mechanisms.
Nephrotoxicity is probably due to ochratoxin A-induced suppression of the collagen regulator mir-29b that results in an increase of translated collagen, fibrotic alteration, and nephropathy. Alternatively, ochratoxin A induces mir-132 upregulation that occurs in neurologic and psychiatric conditions as well as in oxidative stress. Undeniably, mir-132 acts in the reciprocal regulation of autism-related genes MeCP2 and PTEN decreasing the antioxidant Nrf2 that leads to the formation of high levels of reactive oxygen species. Reactive oxygen species, in turn, enhance the expression of mir-200c that impairs antioxidative mechanisms and synaptic plasticity through the reduction of HO-1 and NLGN4X. As for apoptosis, OTA exposure increases mir-122 that suppresses the anti-apoptotic genes Bcl-w and caspase-3 leading to cell death and hepatic damage.
Interestingly, both MECP2 and NLGN4X are involved in neurodevelopmental disorders, including autism, and are mapped on the X chromosome. As autism is a male predominant disorder, a possible contribution of ochratoxin A in its pathogenesis and in its strong male bias can be suggested.
Very few papers report about ochratoxin A-induced deacetylation:cells exposed to OTA underwent to a dramatic block of histone acetyltransferases leading to mitotic arrest and Nrf2 inhibition that, again, lead to reactive oxygen species formation.
Further studies are needed to obtain a complete picture of ochratoxin A-dependent epigenetic effects and to prevent or to counteract them.
Baudrimont I, Sostaric B, Yenot C, Betbeder AM, Dano-Djedje S, Sanni A, Steyn PS, Creppy EE (2001) Aspartame prevents the karyomegaly induced by ochratoxin A in rat kidney. Arch Toxicol 75(3):176–83CrossRefGoogle Scholar
Cai G, Edelmann L, Goldsmith JE et al (2008) Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genet 1:50. https://doi.org/10.1186/1755-8794-1-50CrossRefGoogle Scholar
Castegnaro M, Canadas D, Vrabcheva T et al (2006) Balkan endemic nephropathy: role of ochratoxins A through biomarkers. Mol Nutr Food Res 50(6):519–529CrossRefGoogle Scholar
Chou C, Chang N, Shrestha S, Hsu S, Lin Y, Lee W et al (2015) miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44(D1):D239–D247CrossRefGoogle Scholar
Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127:469–480CrossRefGoogle Scholar
Creppy EE, Chakor K, Fisher MJ et al (1990) The myocotoxin ochratoxin A is a substrate for phenylalanine hydroxylase in isolated rat hepatocytes and in vivo. Arch Toxicol 64(4):279–284CrossRefGoogle Scholar
Jafari N, Dogaheh HP, Bohlooli S et al. (2013) Expression levels of microRNA machinery components Drosha, Dicer and DGCR8 in human (AGS, HepG2, and KEYSE-30) cancer cell lines. Int J Clin Exp Med 6(4):269–274Google Scholar
Jennings P, Weiland C, Limonciel A et al (2012) Transcriptomic alterations induced by ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a ratinvivo model. Arch Toxicol 86:571–589CrossRefGoogle Scholar
Jennings P, Limonciel A, Felice L, Leonard MO (2013) An overview of transcriptional regulation in response to toxicological insult. Arch Toxicol 87:49–72CrossRefGoogle Scholar
Mally A, Pepe G, Ravoori S et al (2005) Ochratoxin a causes DNA damage and cytogenetic effects but no DNA adducts in rats. Chem Res Toxicol 18(8):1253–1261. PubMed PMID: 16097798CrossRefGoogle Scholar
Manners MT, Tian Y, Zhou Z, Ajit SK (2015) MicroRNAs downregulated in neuropathic pain regulate MeCP2 and BDNF related to pain sensitivity. FEBS Open Bio 5:733–740CrossRefGoogle Scholar
Marin-Kuan M, Nestler S, Verguet C et al (2007) MAPK-ERK activation in kidney of male rats chronically fed ochratoxin A at a dose causing a significant incidence of renal carcinoma. Toxicol Appl Pharmacol 224(2):174–181CrossRefGoogle Scholar
McLaughlin J, Padfield PJ, Burt JP, O’Neill CA (2004) Ochratoxin A increases permeability through tight junctions by removal of specific claudin isoforms. Am J Physiol Cell Physiol 287(5):C1412–C1417CrossRefGoogle Scholar
McMasters DR, Angelo Vedani A (1999) Ochratoxin Binding to Phenylalanyl-tRNA Synthetase: Â Computational Approach to the Mechanism of Ochratoxicosis and Its Antagonism. Journal of Medicinal Chemistry 42(16):3075–3086Google Scholar
Zanic-Grubisić T, Zrinski R, Cepelak I, Petrik J, Radić B, Pepeljnjak S (2000) Studies of ochratoxin A-induced inhibition of phenylalanine hydroxylase and its reversal by phenylalanine. Toxicol Appl Pharmacol 167(2):132–139CrossRefGoogle Scholar
Zhu L, Yu T, Qi X, Yang B, Shi L, Luo H, He X, Huang K, Xu W (2016) miR-122 plays an important role in ochratoxin A-induced hepatocyte apoptosis in vitro and in vivo. Toxicol Res 5:160–167CrossRefGoogle Scholar